Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.46 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 2/20 | 0.43 |
| ▸ | PPARA | Q07869 | 3/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 2/20 | 0.43 |
| ▸ | CTSS | P25774 | 2/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 2/20 | 0.42 |
| ▸ | TACR1 | P25103 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14583752 | 1.00 | CASP1 (0.49) | CASP1CA2CTRB1TRPM8ATM | |
| SCHEMBL14583750 | 1.00 | CASP1 (0.49) | CASP1CA2CTRB1TRPM8ATM | |
| SCHEMBL14583738 | 1.00 | CASP1 (0.49) | CASP1CA2CTRB1TRPM8ATM | |
| SCHEMBL6579034 | 0.92 | CASP1 (0.51) | CASP1CA2CTRB1TRPM8ATM | |
| SCHEMBL6578643 | 0.92 | CASP1 (0.51) | CASP1CA2CTRB1TRPM8ATM | |
| SCHEMBL6577081 | 0.89 | CASP1 (0.48) | CASP1CA2CTRB1TRPM8ATM | |
| SCHEMBL6577088 | 0.89 | CASP1 (0.48) | CASP1CA2CTRB1TRPM8ATM | |
| SCHEMBL6328905 | 0.89 | CASP1 (0.48) | CASP1CA2CTRB1TRPM8ATM | |
| SCHEMBL7491284 | 0.89 | CASP1 (0.48) | CASP1CA2CTRB1TRPM8ATM | |
| SCHEMBL5329730 | 0.89 | CASP1 (0.48) | CASP1CA2CTRB1TRPM8ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0984000-B1 | PROCESS FOR PRODUCING AMIDE DERIVATIVES AND INTERMEDIATE COMPOUNDS | JAPAN TOBACCO INC (JP) | 2008-12-03 | — | — | EP | disclosed |
| US-7173059-B2 | Intermediates useful in the synthesis of HIV-protease inhibitors and methods for preparing the same | AGOURON PHARMACEUTICALS, INC. (US) | 2007-02-06 | — | — | US | disclosed |
| US-7173059-B2 | Intermediates useful in the synthesis of HIV-protease inhibitors and methods for preparing the same | AGOURON PHARMACEUTICALS, INC. (US) | 2007-02-06 | — | — | US | disclosed |
| US-20060167277-A1 | New aziridine derivatives and their preparation methods | SAMCHULLY PHARM. CO., LTD. (KR) | 2006-07-27 | — | — | US | disclosed |
| US-7049447-B2 | Aziridine derivatives and their preparation methods | SAMCHULLY PHARM. CO.,LTD. (KR) | 2006-05-23 | — | — | US | disclosed |
| EP-1633704-A2 | INTERMEDIATES USEFUL IN THE SYNTHESIS OF HIV-PROTEASE INHIBITORS AND METHODS FOR PREPARING THE SAME | PFIZER INC. (US) | 2006-03-15 | — | — | EP | disclosed |
| US-20050250949-A1 | Intermediates useful in the synthesis of HIV-protease inhibitors and methods for preparing the same | AGOURON PHARMACEUTICALS INC. | 2005-11-10 | — | — | US | disclosed |
| WO-2004099129-A2 | INTERMEDIATES USEFUL IN THE SYNTHESIS OF HIV-PROTEASE INHIBITORS AND METHODS FOR PREPARING THE SAME | PFIZER INC. (US) | 2004-11-18 | — | — | WO | disclosed |
| US-20040097480-A1 | Aziridine derivatives and their preparation methods | SAMCHULLY PHARM. CO., LTD. (KR) | 2004-05-20 | — | — | US | disclosed |
| WO-2002085893-A1 | NEW AZIRIDINE DERIVATIVES AND THEIR PREPARATION METHODS | SAMCHULLY PHARM. CO., LTD. (KR) | 2002-10-31 | — | — | WO | disclosed |
| US-6194589-B1 | USEFUL AS AN HIV(HUMAN IMMUNODEFICIENCY VIRUS) PROTEASE INHIBITOR; AS X-RAY CONTRAST MEDIUM | JAPAN TOBACCO INC. (JP) | 2001-02-27 | — | — | US | disclosed |
| US-6121468-A | Process for producing amide derivatives and intermediate compounds | JAPAN TOBACCO INC. (JP) | 2000-09-19 | — | — | US | disclosed |
| EP-0984000-A1 | PROCESS FOR PRODUCING AMIDE DERIVATIVES AND INTERMEDIATE COMPOUNDS | Japan Tobacco Inc. (JP) | 2000-03-08 | — | — | EP | disclosed |
| US-6018066-A | Production of amide derivatives and intermediate compounds therefor | JAPAN TOBACCO INC. (JP) | 2000-01-25 | — | — | US | disclosed |
| US-5962704-A | Production of amide derivatives and intermediate compounds therefor | JAPAN TOBACCO INC. (JP) | 1999-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250949-A1 | Intermediates useful in the synthesis of HIV-protease inhibitors and methods for preparing the same | PEPD, DNPEP, PREP | CASP1 377/4885CA2 4032/4885CTRB1 332/4885 |
| US-20060167277-A1 | New aziridine derivatives and their preparation methods | AAAS, AZI2, ATXN2L | CASP1 3479/4885CA2 869/4885CTRB1 1458/4885 |
| US-20040097480-A1 | Aziridine derivatives and their preparation methods | AZI2, AAAS, HRH2 | CASP1 3626/4885CA2 2228/4885CTRB1 1733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.